C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

ABSTRACT:

Background

To better understand a potential association of elevated C-reactive protein (CRP) level with progression of chronic kidney disease (CKD), we examined the relationship of CRP level with the development of end-stage renal disease (ESRD) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Study design

Post hoc analysis of a randomized controlled trial.

Setting & participants

4,038 patients with type 2 diabetes, CKD, and anemia in TREAT.

Predictor

Baseline serum CRP concentrations.

Outcomes

The primary outcome was development of ESRD; secondary outcomes included doubling of serum creatinine level, a composite of ESRD/serum creatinine doubling, and a composite of death or ESRD.

Measurements

We fit unadjusted and adjust

SUBMITTER: Mc Causland FR 

PROVIDER: S-EPMC5123931 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature